Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3586 - Comparison of Concurrent Chemoradiation Therapy Plus Induction Chemotherapy with Cisplatin, Fluorouracil and Docetaxel Versus Gemcitabine and Cisplatin in Advanced Nasopharyngeal Carcinoma.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Zhen Zeng

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

Z. Zeng1, R. Yan2, L. Tu1, Y. Wang2, P. Chen3, F. Luo4, L. Liu5

Author affiliations

  • 1 Department Of Medical Oncology, Cancer Center And State Key Laboratory Of Biotherapy, And Lung Cancer Center, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 2 Department Of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 3 School Of Public Health, Sichuan University, 610041 - Chengdu/CN
  • 4 Department Of Medical Oncology, Cancer Center,and Lung Cancer Center, West China Hospital, Sichuan University, 610041 - Chengdu/CN
  • 5 Department Of Medical Oncology, Cancer Center, State Key Laboratory Of Biotherapy, West China Hospital, Sichuan University, 610041 - Chengdu/CN

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3586

Background

Induction chemotherapy treatment for nasopharyngeal carcinoma (NPC) is controversial. The aim of this study was to evaluate the treatment outcomes and toxicities between two induction chemotherapy regimens, with both followed by concurrent chemoradiotherapy.

Methods

A retrospective study of 113 patients with eligible NPC (stage III–IV NPC with non-distant metastases) treated at the West China Hospital Cancer Center between May 2009 and Dec 2014 was conducted. Among them, 58 patients received cisplatin, fluorouracil, and docetaxel (TPF) and 55 received gemcitabine and cisplatin (GP) induction chemotherapy. Both groups received CCRT incorporating IMRT and cisplatin-based chemotherapy.

Results

The average follow-up time was 51.4 (16.8–98.3) months. Ninety-four patients (83.2%) were alive after 36-months follow-up. The median overall survival (OS) and progression-free survival (PFS) time were 48.3 and 39.7 months, respectively. The 3-year OS for the TPF regimen was 87.9% and 87.4% with GP chemotherapy(P = 0.928). The 3-year PFS of the TPF treatment was 84.5%, while it was 83.5% for the GP group(P = 0.551). OS (Log-Rank P = 0.928) and PFS (Log-Rank P = 0.551) did not differ significantly between the two groups. Patients in the TPF induction chemotherapy plus CCRT group, did not show better LRFS outcomes in comparison to those in the GP induction group (Log-Rank P = 0.073). Furthermore, DMFS rates were not different between the treatment groups (Log-Rank P = 0.892).

Conclusions

There were no significant differences in adverse toxicities or treatment efficacy between the chemotherapy regimens in the treatment of locoregionally advanced NPC. Furthermore, the adverse toxicities were similar and could be tolerated. However, the TPF group had a high proportion of grade 3 or 4 adverse reactions.

Clinical trial identification

Legal entity responsible for the study

Lei Liu.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.